10-QPeriod: Q3 FY2004

QUEST DIAGNOSTICS INC Quarterly Report for Q3 Ended Sep 30, 2004

Filed October 29, 2004For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported solid financial results for the third quarter and the first nine months of 2004. Net revenues increased by 5.6% for the quarter and 8.8% year-to-date, driven by both higher testing volumes and an increase in average revenue per requisition, signaling effective pricing strategies and a favorable shift towards higher-value services like gene-based testing. The company also saw positive momentum in its drugs of abuse testing segment, which had previously been in decline. Profitability also showed improvement, with net income rising to $130 million for the quarter and $373 million for the nine-month period. Operating income margin remained strong at 18.0% for the quarter and 17.4% year-to-date. Management attributed these gains to ongoing Six Sigma and standardization initiatives aimed at improving operational efficiencies, partially offset by strategic investments in operations and some one-time charges. The company also continued its commitment to shareholder returns through share repurchases and initiated quarterly dividend payments.

Key Highlights

  • 1Net revenues increased by 5.6% for Q3 2004 and 8.8% for the first nine months of 2004 compared to the prior year periods.
  • 2Net income rose to $130.1 million for Q3 2004 ($1.26 diluted EPS) and $373.1 million for the nine months ended September 30, 2004 ($3.56 diluted EPS).
  • 3Testing volume, measured by requisitions, increased by 3.3% for the quarter and 5.3% year-to-date, despite a slight negative impact from hurricanes in the Southeast.
  • 4Average revenue per requisition saw improvements of 1.9% for the quarter and 2.9% year-to-date, driven by a shift to higher-value testing.
  • 5Operating income increased to $231.7 million for the quarter (18.0% margin) and $670.6 million for the nine months (17.4% margin).
  • 6The company repurchased approximately $381 million of its common stock year-to-date and initiated quarterly dividend payments.
  • 7Significant debt refinancing was completed in April 2004, establishing a new $500 million senior unsecured revolving credit facility and a $300 million receivables securitization facility.

Frequently Asked Questions

Revenue growth was driven by a combination of increased testing volumes (up 3.3% for the quarter) and higher average revenue per requisition (up 1.9% for the quarter). This increase in average revenue per requisition was attributed to a favorable shift in test mix towards higher-value and gene-based testing, as well as more tests being ordered per requisition. Growth in drugs of abuse testing also contributed positively.

Profitability showed strong improvement. Net income for the third quarter of 2004 was $130.1 million, up from $120.0 million in the prior year. Diluted earnings per share were $1.26 for the quarter. For the first nine months of 2004, net income increased to $373.1 million ($3.56 diluted EPS). Operating income also grew, with margins holding steady or improving year-over-year.

The company's Six Sigma and standardization initiatives are key drivers of operational efficiency. These programs have helped to improve the cost of services and selling, general, and administrative expenses as a percentage of net revenue, contributing to margin expansion and overall profitability.

Quest Diagnostics is actively returning capital to shareholders and managing its capital structure. This includes a significant share repurchase program, with approximately $381 million in stock repurchased year-to-date. The company also initiated quarterly cash dividends. Furthermore, they refinanced their credit facilities in April 2004, enhancing their borrowing capacity and financial flexibility.